Solera Specialty Pharmacy Agrees to Enter into Deferred Prosecution Agreement; Company and CEO
Outcome
OIG enforcement action against Solera Specialty Pharmacy Agrees to Enter into Deferred Prosecution Agreement; Company and CEO for false claims, controlled substance. Penalty: $1.3 million.
Details
Solera Specialty Pharmacy Agrees to Enter into Deferred Prosecution Agreement; Company and CEO — OIG Enforcement (2026)
OIG took enforcement action against Solera Specialty Pharmacy Agrees to Enter into Deferred Prosecution Agreement; Company and CEO in FL in 2026 involving false claims, controlled substance violations in the Independent Pharmacies sector.
Penalty: $1.3 million
Violation types: False Claims, Controlled Substance
Entity type: Pharmacy
Penalty type: Settlement
Location: FL
Source: Solera Specialty Pharmacy Agrees to Enter into Deferred Prosecution Agreement; Company and CEO to Pay $1.31 Million for Submitting False Claims for Anti-Overdose Drug
How Crucible Prevents This
Crucible's billing compliance controls enforce documentation-to-claims reconciliation, requiring clinical attestation before claims submission and flagging billing patterns that deviate from documented care delivery. Crucible's controlled substance tracking enforces DEA-compliant inventory reconciliation, flags prescribing pattern anomalies, and requires segregation of duties for dispensing and record-keeping.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works